A new Toronto HIV clinic is 'bridging the gap' in care with free medication and more
For people without coverage, it can be next to impossible to afford the medication needed to manage HIV. But access to medication isn't the only service that the Toronto People With AIDS Foundation (PWA) offers.
The PWA says it provides immigration services, a food bank and a lunch program to people in Toronto living with HIV.
Ower Oberto, the linkage to care manager at the centre, lives with HIV and came to Canada in 2014.
"I know how stressful it is not having access to medication," he said.
When he first immigrated from Venezuela, Oberto says he didn't know how or even if he could source his medication as a newcomer.
"People living with HIV with precarious immigration status, they wouldn't be able to see a doctor or they have to pay that doctor with money out of pocket," he said. "My medication costs more than $1,200 per month."
Eleven years later, he now works at the PWA's new clinic providing medication to people with HIV.
The clinic was created in partnership with Freddie — a health organization that specializes in HIV prevention and care.
"For us it's been an amazing partnership," Oberto said. "We feel like we are family."
The PWA's one-room clinic is staffed with two nurses and sees patients once a week, on Wednesdays. Clients don't need to be covered by OHIP or insurance, and vary in immigration status, from international students, to visitors and citizens.
"We are bridging all the gaps that have been [letting] … those folks fall into the cracks," Oberto said. "The population we see is a population that is also not easy to support because they don't fill the criteria for the other clinics that are in the city."
Clients are set up with patient assistance programs offered by pharmaceutical companies and leave the clinic medication in hand.
The clinic is located on the third floor of the PWA's building near Jarvis Street and Queen Street E.
Currently the clinic is running a pilot, which began in June. But Oberto has big dreams of scaling up so that it can serve more people with extended hours.
"We are looking forward to [having] more days or more hours, because it's getting busier," he said. "We are looking forward … to [having] a bigger clinic and also to have a pharmacy here downstairs."
Though the HIV-positive population in Canada is relatively small — approximately 62,790 as of 2020, according to a 2022 Public Health Agency of Canada (PHAC) report. That number is now growing despite education and prevention campaigns.
According to PHAC, 2,434 people learned they carried the virus in 2023, up 35 per cent from the previous year.
Of those diagnosed across Canada, PHAC estimates 87 per cent are in treatment and 95 per cent of those have suppressed viral loads, which doctors say makes the virus undetectable, untransmittable and prevents it from progressing to AIDS.
A decade ago, the United Nations set a goal to eradicate the HIV epidemic by 2030.
"This is the best way to do it," Oberto said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
6 minutes ago
- Associated Press
Zentrogene Medical Laboratory Announces Vision for National Healthcare Self-Reliance and Scientific Sovereignty in Cambodia
Zentrogene Medical Laboratory transforms Cambodia's healthcare landscape with advanced genetic testing, reducing dependency and building national resilience. Cambodia, August 10, 2025 -- In Cambodia's pursuit of greater scientific and healthcare self-reliance, Zentrogene Medical Laboratory is playing a pivotal role. Since my appointment as Chief Operating Officer, I have worked diligently to create a future where Cambodians no longer rely on foreign powers for essential healthcare services, particularly genetic testing. For too long, Cambodian patients and healthcare providers faced the challenge of sending critical genetic samples abroad due to the lack of local technology and expertise. This dependency often resulted in delayed results, increased costs, and limited control over the outcome. At Zentrogene, we have transformed this scenario by creating a fully equipped genetic testing laboratory that now serves as a cornerstone of Cambodia's medical independence. Pioneering a New Era in Genetic Testing At Zentrogene, our mission is to revolutionize genetic testing in Cambodia, empowering individuals and healthcare professionals with precise insights for proactive health management and personalized treatments. With the establishment of Cambodia's most advanced genetic laboratory, we have achieved this goal. The lab is equipped with a Next-Generation Sequencing (NGS) platform, a state-of-the-art facility, and a team of experts with international experiences and educational backgrounds from the UK, the US, China, and Hong Kong. We now offer a range of genetic testing services that allow for faster, safer, and locally-controlled diagnostic results, eliminating the need for international outsourcing. These services include: Genetic Testing: Medical Testing: By offering these services locally, we are able to reduce the dependency on foreign laboratories, ensuring that Cambodian doctors can rely on world-class testing right at home. This approach enhances the speed and efficiency of healthcare delivery, while also reducing costs and improving quality control. A Strategic Asset for National Resilience The mission of Zentrogene extends beyond individual healthcare. By localizing cutting-edge genetic capabilities, we are building a strategic asset for Cambodia, one that strengthens not only healthcare but also other critical sectors. It strengthens Cambodia's national resilience by establishing a foundation for scientific innovation that serves various sectors, including public health, agriculture, environmental science, and scientific research. Our advanced NGS technology supports: Through these efforts, Zentrogene is helping to build a self-reliant, scientifically empowered Cambodia - one that can address complex challenges with homegrown expertise and technology. In short, genetics is no longer a foreign asset we borrow; it is now a Cambodian strength we grow. Supporting Cambodian Research and Innovation Zentrogene is deeply committed to supporting the next generation of Cambodian researchers. We offer cost-free testing services and sequencing assistance to academic and scientific institutions conducting genetic research and precision medicine studies. Our goal is to foster an environment where Cambodian research thrives, using the latest technology and eliminating the need for outsourcing. We actively seek partnerships with institutions across all ranges of sectors, ranging from healthcare to agriculture, environmental science, and public health. By empowering local researchers with cutting-edge technology, we are ensuring that Cambodia's scientific future is in the hands of our own people. A Commitment to Cambodia's Future In this moment, the importance of our national healthcare capability has never been clearer. Cambodia must not and will not depend on the other country that threatens our well-being in times of conflict. At Zentrogene, our dedication to Cambodia's healthcare system and scientific growth is unwavering. With our state-of-the-art laboratory and world-class expertise, we are ensuring that Cambodians have access to the latest advancements in healthcare and genetic testing without relying on external sources. Furthermore, under the highly esteemed and visionary leadership of Samdech Moha Borvor Thipadei HUN MANET, Prime Minister of the Kingdom of Cambodia, the nation continues to enjoy peace and stability, which is a critical foundation for progress in healthcare and scientific innovation. His government's clear vision has prioritized the development of a resilient healthcare system, the advancement of medical science, and the reduction of dependency on foreign services. Our vision is one of national self-reliance in science and medicine, where Cambodia's people are empowered by local solutions that are tailored to our unique needs. By continuing to advance the field of genetic testing, Zentrogene is proud to contribute to a stronger, more resilient healthcare system in Cambodia. About Zentrogene Zentrogene Medical Laboratory is Cambodia's first and only laboratory focused on advanced genetic testing. The company's mission is to empower the Cambodian healthcare sector by providing cutting-edge diagnostic services and fostering the development of scientific and medical self-reliance in Cambodia. Media Contact Chanraksmey Veal COO, Zentrogene Medical Laboratory Email: [email protected] Facebook LinkedIn Contact Info: Name: Chanraksmey Veal Email: Send Email Organization: Zentrogene Medical Laboratory Website: Release ID: 89166320 Should any problems, inaccuracies, or doubts arise from the content contained within this press release, we kindly request that you inform us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is at the core of our commitment to our readers.
Yahoo
34 minutes ago
- Yahoo
Vitalhub Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Vitalhub's Fair Values from the Community and select yours Vitalhub (TSE:VHI) Second Quarter 2025 Results Key Financial Results Revenue: CA$23.9m (up 47% from 2Q 2024). Net income: CA$1.77m (up from CA$335.1k loss in 2Q 2024). Profit margin: 7.4% (up from net loss in 2Q 2024). EPS: CA$0.032 (up from CA$0.007 loss in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Vitalhub Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 8.1%. Earnings per share (EPS) missed analyst estimates by 25%. Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in North America. Performance of the market in Canada. The company's shares are up 3.2% from a week ago. Risk Analysis You still need to take note of risks, for example - Vitalhub has 1 warning sign we think you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.


Axios
35 minutes ago
- Axios
RFK Jr.'s vaccine pullback stokes fears of lost medical breakthroughs
Health Secretary Robert F. Kennedy Jr.'s decision to cut federal funding for mRNA vaccine research is the latest in a series of moves that have the potential to crush future medical breakthroughs and accelerate a brain drain. Why it matters: America has historically led the world in scientific innovation — driving economic growth, strengthening national security, and attracting global talent. But scientists, including some who served in Trump's first administration, warn that lead is slipping away. The mRNA divestment "risks stalling progress in some of the most promising areas of modern medicine," Jerome Adams, surgeon general during the first Trump administration and now a professor at Purdue University, told Axios. "Walking away from this technology now would be like pulling funding from antibiotics after penicillin or from computers after the microchip. It's short-sighted and puts us at a disadvantage globally." State of play: Kennedy said last week that HHS's Biomedical Advanced Research and Development Authority would pull nearly $500 million worth of contracts with universities, drug companies and other labs working on new mRNA vaccines. No new mRNA-based projects will be launched as the administration shifts to "safer, broader vaccine platforms," he added. Scientists refute the implication that mRNA vaccines are unsafe. The technology that brought mRNA COVID vaccines in Trump's first term has been in development for decades. Large scientific trials and real-world data have shown that the vaccines are safe and effective — and capable of training the body's immune system to create antibodies to fight a host of afflictions. HHS, when asked for the research on which Kennedy based this decision, sent Axios a link to a citation collection put together by anti-COVID vaccine advocates, including Steven Hatfill, who promoted the use of the antimalarial drug hydroxychloroquine to treat the virus before vaccines were available despite reports of safety issues. Friction point: mRNA technology is what allowed the most common COVID vaccines to be deployed so quickly, and it's essential to responding to new viral pandemic threats, said Cynthia Leifer, a professor of immunology at Cornell University's College of Veterinary Medicine. "When we have a pandemic, we need to act quickly. We don't have time to wait several years or decades to do testing of older platforms the way they were normally done in years past," she said. "The newer technology could allow us to move so much faster to develop and have these vaccines rolled out to protect people when a pandemic is ongoing," Leifer added. Researchers are also studying how mRNA technology could treat or prevent cancer, HIV, and other chronic diseases — and the science so far is promising. Now, they're worried that progress could be lost. "If we stop now, we could delay or even miss the next generation of cures entirely," said Adams, the former surgeon general. Zoom out: Scientists say some of Kennedy's other changes are stifling innovation, too. Kennedy is working to implement massive staff cuts at HHS, reduce funding for research labs' overhead costs and end National Institutes of Health grants for a wide swath of projects. The cuts, along with the broader Trump administration's immigration restrictions, has already started to steer promising international scientific talent away from the country. Kennedy also is reportedly considering overhauling the U.S. Preventive Services Task Force, whose independent experts establish care and coverage guidelines to account for advances in medical treatments and new disease trends. Its past work included recommending beginning mammograms at 40, which has been credited with saving thousands of lives. The other side: HHS denies that its changes will stymie medical advances. "Those concerns are unfounded and not supported with facts," HHS Communications Director Andrew Nixon told Axios. Kennedy's decision to cut BARDA funding for mRNA work won't affect other government uses involving the technology, HHS said. The Centers for Disease Control and Prevention has endorsed mRNA COVID vaccines for most adults. Between the lines: An independent and bipartisan commission warned Congress in April that China has already pulled ahead of the U.S. in key life sciences areas. The U.S. can stay dominant, but it only has a few years to strengthen its position — and it needs to put significant resources into biotechnology resources, the commission's report said. Reality check: It's impossible to know whether breakthroughs actually won't happen as a result of these policy changes, or which advances we could miss out on. "That is a long-term impact that is hard to measure. What cure wasn't found? What question wasn't asked and investigated?" Richard Besser, CEO of the Robert Wood Johnson Foundation, said. mRNA therapy start-ups are also still raising private investment, which could keep research moving.